Platelet-activating factor (PAF) is a potent inflammatory agonist. In Swiss albino mice,
intraperitoneal injection of PAF causes
sudden death with oxidative stress and
disseminated intravascular coagulation (
DIC), characterized by prolonged prothrombin time,
thrombocytopenia, reduced
fibrinogen content, and increased levels of
fibrinogen degradation products. However, the underlying mechanism(s) is unknown. The PAF-R antagonist
WEB-2086 protected mice against PAF-induced death by reducing
DIC and oxidative stress. Accordingly, general
antioxidants such as
ascorbic acid, α-
tocopherol,
gallic acid, and
N-acetylcysteine partially protected mice from PAF-induced death.
N-acetylcysteine, a clinically used
antioxidant, prevented death in 67% of mice, ameliorated
DIC characteristics and histological alterations in the liver, and reduced oxidative stress.
WEB-2086 suppressed H2O2-mediated oxidative stress in isolated mouse peritoneal macrophages, suggesting that PAF signaling may be a downstream effector of
reactive oxygen species generation. PAF stimulated all three (ERK, JNK, and p38) of the MAP-
kinases, which were also inhibited by
N-acetylcysteine. Furthermore, a JNK inhibitor (
SP600125) and ERK inhibitor (
SCH772984) partially protected mice against PAF-induced death, whereas a
p38 MAP-kinase inhibitor (
SB203580) provided complete protection against
DIC and death. In human platelets, which have the canonical PAF-R and functional MAP-
kinases, JNK and p38 inhibitors abolished PAF-induced platelet aggregation, but the ERK inhibitor was ineffective. Our studies identify
p38 MAP-kinase as a critical, but unrecognized component in PAF-induced mortality in mice. These findings suggest an alternative therapeutic strategy to address PAF-mediated pathogenicity, which plays a role in a broad range of inflammatory diseases.